Cirrhotic Ascites Treatment With Satavaptan in Patients With Ascites Due to Cirrhosis of the Liver (CATS)

PHASE3CompletedINTERVENTIONAL
Enrollment

463

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2008

Conditions
AscitesLiver Cirrhosis
Interventions
DRUG

Satavaptan

oral administration once daily

DRUG

placebo

oral administration once daily

Trial Locations (21)

08807

Sanofi-Aventis Administrative Office, Bridgewater

Unknown

Sanofi-Aventis Administrative Office, Buenos Aires

Sanofi-Aventis Administrative Office, Cove

Sanofi-Aventis Administrative Office, Diegem

Sanofi-Aventis Administrative Office, São Paulo

Sanofi-Aventis Administrative Office, Laval

Sanofi-Aventis Administrative Office, Santiago

Sanofi-Aventis Administrative Office, Zagreb

Sanofi-Aventis Administrative Office, Hørsholm

Sanofi-Aventis Administrative Office, Paris

Sanofi-Aventis Administrative Office, Budapest

Sanofi-Aventis Administrative Office, Netanya

Sanofi-Aventis Administrative Office, Milan

Sanofi-Aventis Administrative Office, Gouda

Sanofi-Aventis Administrative Office, Warsaw

Sanofi-Aventis Administrative Office, Porto Salvo

Sanofi-Aventis Administrative Office, Bucharest

Sanofi-Aventis Administrative Office, Moscow

Sanofi-Aventis Administrative Office, Madrid

Sanofi-Aventis Administrative Office, Bromma

Sanofi-Aventis Administrative Office, Guildford

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Sanofi

INDUSTRY

NCT00358878 - Cirrhotic Ascites Treatment With Satavaptan in Patients With Ascites Due to Cirrhosis of the Liver (CATS) | Biotech Hunter | Biotech Hunter